EMERGENT BIOSOLUTIONS INC. Unrecognized Tax Benefits, Increase Resulting from Acquisition
EMERGENT BIOSOLUTIONS INC. (EBS) reported Unrecognized Tax Benefits, Increase Resulting from Acquisition of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition · last filed 2021-02-19
- EMERGENT BIOSOLUTIONS INC. unrecognized tax benefits, increase resulting from acquisition for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- EMERGENT BIOSOLUTIONS INC. unrecognized tax benefits, increase resulting from acquisition for fiscal 2018 was $6.50M.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Acquisition 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2018-12-31 | $6.50M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |